SCHEMBL12764985

SCHEMBL12764985

CCOC(=O)c1cccc2c3c(c(=O)[nH]c12)CCCC3

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLEC4M Q9H2X3 1/20 0.53
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 4/20 0.49
MAPT P10636 2/20 0.49
GFER P55789 1/20 0.47
ALOX15 P16050 2/20 0.46
HSD17B10 Q99714 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.45
TP53 P04637 1/20 0.44
CDC25B P30305 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12764944 0.86 CLEC4M (0.49) CLEC4MALDH1A1KDM4EMAPTMAPK1
SCHEMBL12764935 0.85 PARP1 (0.61) CLEC4MALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL12764968 0.85 GFER (0.49) ALDH1A1KDM4EMAPTGFERALOX15
SCHEMBL12764963 0.83 GFER (0.47) ALDH1A1KDM4EMAPTGFERALOX15
SCHEMBL12764941 0.79 MTHFD2 (0.54) CLEC4MALDH1A1L3MBTL1LMNATSHR
SCHEMBL7500905 0.77 PLK4 (0.62) CLEC4MALDH1A1KDM4EMAPTALOX15
SCHEMBL11737708 0.77 CLEC4M (0.58) CLEC4MALDH1A1KDM4EMAPTHSD17B10
SCHEMBL30804630 0.73 KDM4E (0.62) CLEC4MALDH1A1KDM4EMAPTHSD17B10
SCHEMBL6045360 0.73 KDM4E (0.62) CLEC4MALDH1A1KDM4EMAPTHSD17B10
SCHEMBL12765014 0.72 PARP1 (0.45) KDM4EMAPTGFERALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071136-A1 NOVEL TRICYCLIC PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC (US) 2011-03-24 US disclosed
US-20110071136-A1 NOVEL TRICYCLIC PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC (US) 2011-03-24 US disclosed
WO-2011035019-A1 NOVEL TRICYCLIC PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071136-A1 NOVEL TRICYCLIC PROTEIN KINASE MODULATORS PACSIN2, CSNK2A3, CKS2 CLEC4M 2642/4885ALDH1A1 4683/4885KDM4E 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.